Gilead Sciences (GILD) Cash from Operations (2009 - 2026)

Gilead Sciences (GILD) has reported Cash from Operations for 18 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 332.04% year-over-year to $3.6 billion; the trailing twelve-month figure through Jun 2026 stood at $13.6 billion (up 37.33% YoY), and the FY2025 full-year result was $10.0 billion, down 7.47% from the prior year.
• Cash from Operations grew to $3.6 billion in Q2 2026 per GILD's latest filing, from $2.5 billion in the prior quarter.
• Across five years, Cash from Operations topped out at $4.3 billion in Q3 2024 and bottomed at $827.0 million in Q2 2025.
• Historically, Cash from Operations has averaged $2.4 billion across 5 years, with a median of $2.3 billion in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations plunged 43.33% in 2024, then jumped 332.04% in 2026.
• Over 5 years, Cash from Operations stood at $2.6 billion in 2022, then slipped by 15.5% to $2.2 billion in 2023, then jumped by 37.16% to $3.0 billion in 2024, then grew by 11.83% to $3.3 billion in 2025, then climbed by 7.39% to $3.6 billion in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $3.6 billion, $2.5 billion, and $3.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.